Is Recursion Pharmaceuticals (RXRX) a buy or sell right now?
Based on aggregated sentiment from Reddit, X, and News sources, Recursion Pharmaceuticals (RXRX) currently carries an Adanos hold signal with 66/100 conviction. The current cross-source average reads 44% bullish across 3 active sources. Those sources contribute 117 tracked mentions over the last 7 days. This is a sentiment-based reading, not financial advice.
What does Reddit say about RXRX stock?
Reddit discussion around Recursion Pharmaceuticals (RXRX) is fairly quiet with 40 mentions across 8 tracked subreddits. The tone is 24% bullish with stable momentum, suggesting steady interest over the past week.
What is the sentiment on RXRX stock?
Recursion Pharmaceuticals (RXRX) sentiment is bearish across all 3 tracked sources. X reads 68% bullish, News reads 40% bullish, and reddit coverage is the most negative at 24% bullish. The combined signal points to broad mixed pressure with 66/100 conviction.
Why does RXRX carry a hold signal right now?
Social sentiment data shows consistently bearish discussion around Recursion Pharmaceuticals (RXRX). All 3 tracked sources lean negative, with reddit being the most bearish at 24% bullish. The hold signal carries 66/100 conviction.
What is driving Recursion Pharmaceuticals (RXRX) sentiment right now?
X is the dominant discussion channel with 72 mentions (62% of total volume). Reddit contributes 40 mentions and News contributes 5 mentions. Sentiment is bearish across all sources.
What does the Adanos hold signal mean for Recursion Pharmaceuticals (RXRX)?
The Adanos signal blends bullish ratio, buzz score, source breadth, and 7-day momentum into a single buy/sell reading. RXRX's hold signal at 66/100 conviction reflects consistently bearish sentiment across multiple platforms. It is a research shortcut, not financial advice.
How fresh is this RXRX sentiment data?
The RXRX sentiment page is regenerated from the latest 7-day tracking window at each build. Data reflects the most recent Reddit posts, tweets, and news articles available in the current publishing cycle.